<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Starvaggi J</submitter><funding>PRIN_2022PNRR</funding><pagination>24</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12845239</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;b>Background:&lt;/b> In this study, we report a novel series of proline- and pipecolic acid-based small molecules designed as allosteric inhibitors of the NS2B/NS3 serine proteases from dengue and Zika viruses, key targets in antiviral drug discovery. &lt;b>Results:&lt;/b> Enzymatic studies revealed that &lt;i>S&lt;/i>-proline derivatives bearing electron-withdrawing substituents on the aromatic ring, particularly that with a trifluoromethyl group in &lt;i>meta&lt;/i> position (i.e., compound &lt;b>3&lt;/b>, IC&lt;sub>50&lt;/sub> = 5.0 µM), were the most potent against DENV NS2B/NS3, while nitro-substituted inhibitors were mostly effective only against the ZIKV protease. &lt;i>R&lt;/i>-configured pipecolic acid-based derivatives were the only ones active against DENV NS2B/NS3, even if the mid-micromolar range; however, they demonstrated improved cellular efficacy since inhibitors &lt;b>24&lt;/b> and &lt;b>27&lt;/b> exhibiting strong activity in a DENV2 protease reporter gene assay (EC&lt;sub>50&lt;/sub> = 5.2 and 5.1 µM, respectively). All compounds showed no cytotoxicity (CC&lt;sub>50&lt;/sub> > 100 µM) and were selective for the viral protease over off-target serine proteases. Structure-based approaches were exploited to map the druggable allosteric site close to Asn152. &lt;b>Conclusions:&lt;/b> Our findings led us to identify proline and pipecolic acid-based inhibitors as promising leads for the development of selective flaviviral NS2B/NS3 allosteric inhibitors.</pubmed_abstract><journal>Pharmaceuticals (Basel, Switzerland)</journal><pubmed_title>Development of Novel Proline- and Pipecolic Acid-Based Allosteric Inhibitors of Dengue and Zika Virus NS2B/NS3 Protease.</pubmed_title><pmcid>PMC12845239</pmcid><funding_grant_id>P2022KCW3LP2022KCW3L_001 and P2022KCW3LP2022KCW3L_002</funding_grant_id><pubmed_authors>Lang J</pubmed_authors><pubmed_authors>Klein C</pubmed_authors><pubmed_authors>Starvaggi J</pubmed_authors><pubmed_authors>Belgiovine V</pubmed_authors><pubmed_authors>Nicolotti O</pubmed_authors><pubmed_authors>Di Chio C</pubmed_authors><pubmed_authors>Ettari R</pubmed_authors><pubmed_authors>Previti S</pubmed_authors><pubmed_authors>Trisciuzzi D</pubmed_authors><pubmed_authors>Di Maro S</pubmed_authors><pubmed_authors>Zappala M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of Novel Proline- and Pipecolic Acid-Based Allosteric Inhibitors of Dengue and Zika Virus NS2B/NS3 Protease.</name><description>&lt;b>Background:&lt;/b> In this study, we report a novel series of proline- and pipecolic acid-based small molecules designed as allosteric inhibitors of the NS2B/NS3 serine proteases from dengue and Zika viruses, key targets in antiviral drug discovery. &lt;b>Results:&lt;/b> Enzymatic studies revealed that &lt;i>S&lt;/i>-proline derivatives bearing electron-withdrawing substituents on the aromatic ring, particularly that with a trifluoromethyl group in &lt;i>meta&lt;/i> position (i.e., compound &lt;b>3&lt;/b>, IC&lt;sub>50&lt;/sub> = 5.0 µM), were the most potent against DENV NS2B/NS3, while nitro-substituted inhibitors were mostly effective only against the ZIKV protease. &lt;i>R&lt;/i>-configured pipecolic acid-based derivatives were the only ones active against DENV NS2B/NS3, even if the mid-micromolar range; however, they demonstrated improved cellular efficacy since inhibitors &lt;b>24&lt;/b> and &lt;b>27&lt;/b> exhibiting strong activity in a DENV2 protease reporter gene assay (EC&lt;sub>50&lt;/sub> = 5.2 and 5.1 µM, respectively). All compounds showed no cytotoxicity (CC&lt;sub>50&lt;/sub> > 100 µM) and were selective for the viral protease over off-target serine proteases. Structure-based approaches were exploited to map the druggable allosteric site close to Asn152. &lt;b>Conclusions:&lt;/b> Our findings led us to identify proline and pipecolic acid-based inhibitors as promising leads for the development of selective flaviviral NS2B/NS3 allosteric inhibitors.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-13T03:19:47.754Z</modification><creation>2026-06-13T03:12:01.199Z</creation></dates><accession>S-EPMC12845239</accession><cross_references><pubmed>41599626</pubmed><doi>10.3390/ph19010024</doi></cross_references></HashMap>